Evidence
J Hepatol. 2024 May 22:S0168-8278(24)00359-3. doi: 10.1016/j.jhep.2024.05.024. Online ahead of print.
NO ABSTRACT
PMID:38789012 | DOI:10.1016/j.jhep.2024.05.024
Estimated reading time: 1 minute(s)
Latest: Psychiatryai.com #RAISR4D Evidence
Cool Evidence: Engaging Young People and Students in Real-World Evidence
Real-Time Evidence Search [Psychiatry]
AI Research
The Transition in Terminology: From Non-alcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) to Metabolic-associated Steatotic Liver Disease (MASLD)
🌐 90 Days
AI Virtual Reality Related Evidence Matrix
- EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
- Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics
- Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD
- Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD
- Response to: The Synergism of Public Health Policies and Social Work May Reduce Mortality from Cancer, Liver Disease and Cardiovascular Disease
- Spatial genomics: mapping human steatotic liver disease
- MAFLD as part of systemic metabolic dysregulation
- MAFLD as part of systemic metabolic dysregulation
- Pediatric metabolic (dysfunction)-associated fatty liver disease: current insights and future perspectives
- An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD)
- Targeting metabolic-associated fatty liver disease in diabetic kidney disease: A call to action
- New nomenclature for fatty liver disease
- Incretin-based investigational therapies for the treatment of MASLD/MASH
- Hepatic steatosis, metabolic dysfunction and risk of mortality: findings from a multinational prospective cohort study
- Hepatic steatosis, metabolic dysfunction and risk of mortality: findings from a multinational prospective cohort study
- Coronary artery disease as a risk factor for metabolic dysfunction-associated steatotic liver disease and liver fibrosis
- Comparative study of MAFLD as a predictor of metabolic disease treatment for NAFLD
- Analysis of non-alcoholic fatty liver disease differences from metabolic dysfunction-associated fatty liver disease based on clinical features
- Prognostic value of metabolic dysfunction-associated steatotic liver disease over coronary computed tomography angiography findings: comparison with no-alcoholic fatty liver disease
- Angiocrine signaling in sinusoidal homeostasis and liver diseases
- Galectin-3 and Severity of Liver Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease
- Epidemiology, screening, and Co-management of type 2 diabetes mellitus and Metabolic-dysfunction associated steatotic liver disease
- THE GLOBAL EPIDEMIOLOGY OF NON-ALCOHOLIC FATTY LIVER DISEASE AND NON-ALCOHOLIC STEATOHEPATITIS AMONG PATIENTS WITH TYPE 2 DIABETES
- Coexistence of metabolic-associated fatty liver disease and autoimmune or toxic liver disease
- Muscle strength and non-alcoholic fatty liver disease/metabolic-associated fatty liver disease
- Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease
- Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease
- Impact of the diagnosis of metabolic dysfunction-associated fatty liver disease and non-alcoholic fatty liver disease in patients undergoing liver transplantation for hepatocellular carcinoma
- Interplay between metabolic dysfunction-associated fatty liver disease and renal function: An intriguing pediatric perspective
- Guidelines for the prevention and treatment of metabolic dysfunction-associated (non-alcoholic) fatty liver disease (Version 2024)
- Guidelines for the prevention and treatment of metabolic dysfunction-associated (non-alcoholic) fatty liver disease (Version 2024)
- Metabolic Dysfunction-associated Fatty Liver Disease: An Urgent Call for Global Action
- Changes in the terminology and diagnostic criteria of non-alcoholic fatty liver disease: Implications and opportunities
- Dietary characteristics associated with the risk of non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease in non-obese Japanese participants: A cross-sectional study
- Dietary characteristics associated with the risk of non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease in non-obese Japanese participants: A cross-sectional study
- Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD)
- Metabolic-Associated Steatotic Liver Disease (MASLD): A New Term for a More Appropriate Therapy in Pediatrics?
- Update in lean metabolic dysfunction-associated steatotic liver disease
- Update in lean metabolic dysfunction-associated steatotic liver disease
- Role of the angiopoietin-like protein family in the progression of NAFLD
- Spleen volume is independently associated with non-alcoholic fatty liver disease, liver volume and liver fibrosis
- From NAFLD to NASH: Understanding the spectrum of non-alcoholic liver diseases and their consequences
- Genome-wide association study of metabolic dysfunction-associated fatty liver disease in a Korean population
- Associations of perfluoroalkyl substances with metabolic-associated fatty liver disease and non-alcoholic fatty liver disease: NHANES 2017-2018
- Electrocardiographic Abnormalities in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis
- Hepatic extracellular ATP/adenosine dynamics in zebrafish models of alcoholic and metabolic steatotic liver disease
- The fatty acid omega hydroxylase genes (CYP4 family) in the progression of metabolic dysfunction-associated steatotic liver disease (MASLD): An RNA sequence database analysis and review
- Inflammatory liver diseases and susceptibility to sepsis
- The role and mechanism of SUMO modification in liver disease
- An international multidisciplinary consensus on pediatric metabolic dysfunction-associated fatty liver disease
- Multiscale 3D genome organization underlies duck fatty liver with no adipose inflammation or serious injury
- The gut-liver axis in fatty liver disease: role played by natural products
- Cardiovascular disease in patients with metabolic dysfunction-associated steatohepatitis compared with metabolic dysfunction-associated steatotic liver disease and other liver diseases: A systematic review
- Cardiovascular disease in patients with metabolic dysfunction-associated steatohepatitis compared with metabolic dysfunction-associated steatotic liver disease and other liver diseases: A systematic review
- Review article: Hepatic steatosis and its associations with acute and chronic liver diseases
- Sex difference in skeletal muscle mass in relation to metabolic dysfunction-associated steatotic liver disease: a propensity score matching study
- TET3 boosts hepatocyte autophagy and impairs non-alcoholic fatty liver disease by increasing ENPP1 promoter hypomethylation
- Anxiety and depression in metabolic-associated steatotic liver disease: relation with socio-demographic features and liver disease severity
- Metabolic dysfunction-associated fatty liver disease and low muscle strength: A comment
- Patients with Celiac Disease Have High Prevalence of Fatty Liver and Metabolic Syndrome
- Interplay of metabolic dysfunction-associated fatty liver disease and papillary thyroid carcinoma: insights from a Chinese cohort
- Associations of dietary sugars with liver stiffness in Latino adolescents with obesity differ on PNPLA3 and liver disease severity
- Prevalence of at-risk MASH, MetALD and alcohol-associated steatotic liver disease in the general population
- Clinical status and challenges of new drugs for metabolic dysfunction-associated fatty liver disease
Evidence Blueprint
The Transition in Terminology: From Non-alcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) to Metabolic-associated Steatotic Liver Disease (MASLD)
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
The Transition in Terminology: From Non-alcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) to Metabolic-associated Steatotic Liver Disease (MASLD)
🌐 365 Days
AI Virtual Reality Related Evidence Matrix
- Metabolic dysfunction-associated steatotic liver disease (MASLD) definition is better than MAFLD criteria for lean patients with non-alcoholic fatty liver disease (NAFLD)
- Metabolic dysfunction-associated steatotic liver disease: Where does non-alcoholic fatty liver disease in liver transplant recipients fit in this new definition?
- Corrigendum to "SIRT5 rs12216101 T>G variant is associated with liver damage and mitochondrial dysfunction in patients with non-alcoholic fatty liver disease" [J Hepatol 80 (2024) 10-19]
- EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
- Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease
- Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics
- Effect of the nomenclature of non-alcoholic fatty liver disease on diagnosis and treatment of fatty liver disease concomitant with other liver diseases
- Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD
- Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD
- Response to: The Synergism of Public Health Policies and Social Work May Reduce Mortality from Cancer, Liver Disease and Cardiovascular Disease
- Letter to editor: Associations between per- and polyfluoroalkyl substances and adolescent non-alcoholic fatty liver disease
- Metabolism-related signalling pathways involved in the pathogenesis and development of metabolic dysfunction-associated steatotic liver disease
- Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity
- From metabolic dysfunction-associated fatty liver disease to metabolic dysfunction-associated steatotic liver disease: Controversy and consensus
- Spatial genomics: mapping human steatotic liver disease
- Metabolic dysfunction: The silenced connection with fatty liver disease
- Association of metabolic-dysfunction associated steatotic liver disease with polycystic ovary syndrome
- MAFLD as part of systemic metabolic dysregulation
- MAFLD as part of systemic metabolic dysregulation
- Pediatric metabolic (dysfunction)-associated fatty liver disease: current insights and future perspectives
- Ultrasonographic findings of metabolic dysfunction-associated fatty liver disease: A comparative study with non-alcoholic fatty liver disease and clinical characteristics
- Breaking new ground: MASLD vs. MAFLD-which holds the key for risk stratification?
- The double roles of T cell-mediated immune response in the progression of MASLD
- An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD)
- Comparison of NAFLD, MAFLD and MASLD characteristics and mortality outcomes in United States adults
- Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma
- MASLD: a systemic metabolic disorder with cardiovascular and malignant complications
- Can we use old NAFLD data under the new MASLD definition?
- Therapeutic management of metabolic dysfunction associated steatotic liver disease
- Mortality in metabolic dysfunction-associated steatotic liver disease: A nationwide population-based cohort study
- Targeting metabolic-associated fatty liver disease in diabetic kidney disease: A call to action
- New nomenclature for fatty liver disease
- Incretin-based investigational therapies for the treatment of MASLD/MASH
- Nuclear miR-204-3p mitigates metabolic dysfunction-associated steatotic liver disease in mice
- Nuclear miR-204-3p mitigates metabolic dysfunction-associated steatotic liver disease in mice
- The Global Epidemic of Metabolic Fatty Liver Disease
- Hepatic steatosis, metabolic dysfunction and risk of mortality: findings from a multinational prospective cohort study
- Hepatic steatosis, metabolic dysfunction and risk of mortality: findings from a multinational prospective cohort study
- Coronary artery disease as a risk factor for metabolic dysfunction-associated steatotic liver disease and liver fibrosis
- Comparative study of MAFLD as a predictor of metabolic disease treatment for NAFLD
- Analysis of non-alcoholic fatty liver disease differences from metabolic dysfunction-associated fatty liver disease based on clinical features
- Increased Risk of Colorectal Adenomas with Metabolic-Associated Fatty Liver Disease Components
- Adipose-derived extracellular vesicles - a novel cross-talk mechanism in insulin resistance, non-alcoholic fatty liver disease, and polycystic ovary syndrome
- Bioactive signaling lipids as drivers of chronic liver diseases
- Fatty liver disease's renaming impacts on drug clinical trials
- The Prothrombotic Tendency of Metabolic-Associated Fatty Liver Disease
- Prognostic value of metabolic dysfunction-associated steatotic liver disease over coronary computed tomography angiography findings: comparison with no-alcoholic fatty liver disease
- Metabolic-associated fatty liver disease: a selective review of pathogenesis, diagnostic approaches, and therapeutic strategies
- Angiocrine signaling in sinusoidal homeostasis and liver diseases
- Galectin-3 and Severity of Liver Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease
- Epidemiology, screening, and Co-management of type 2 diabetes mellitus and Metabolic-dysfunction associated steatotic liver disease
- From Liver to Brain: How MAFLD/MASLD Impacts Cognitive Function
- THE GLOBAL EPIDEMIOLOGY OF NON-ALCOHOLIC FATTY LIVER DISEASE AND NON-ALCOHOLIC STEATOHEPATITIS AMONG PATIENTS WITH TYPE 2 DIABETES
- Dietary and pharmacological treatment in patients with metabolic-dysfunction associated steatotic liver disease
- From non-alcoholic fatty liver disease (NAFLD) to steatotic liver disease (SLD): an ongoing journey towards refining the terminology for this prevalent metabolic condition and unmet clinical need
- Coexistence of metabolic-associated fatty liver disease and autoimmune or toxic liver disease
- Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease
- Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver disease
- Muscle strength and non-alcoholic fatty liver disease/metabolic-associated fatty liver disease
- Screening, Diagnosis, and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD): Application of Society Guidelines to Clinical Practice
- Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease
- Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease
- Prevalence, distribution and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings
- Research progress of celastrol on the prevention and treatment of metabolic associated fatty liver disease